Alina I. Gilyazova

Alina I. Gilyazova

Auto-generated profile, based on publicly available information

Alina I. Gilyazova

Kazan State Medical University

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2024 in Advances in molecular oncology
Verified
Journal Article
Open access
PDF file
AGAigul Galembikova
Aigul Galembikova
PDPavel Dunaev
Pavel Dunaev
TGTatyana Gessel
Tatyana Gessel
AGA. I. Gilyazova
A. I. Gilyazova
AGAlina Galyautdinova
Alina Galyautdinova
Sergei BoichukSergei Boichuk
Sergei Boichuk
Introduction. Microtubules are highly dynamic polymers of α, β-tubulin dimers involves in a broad spectrum of the processes, such as intracellular transport and cell proliferation. This makes them an attractive molecular target for anti-cancer therapies. Substances that affect the dynamic state of tubulin microtubules are known as the mitotic poisons that are effectiveand widely used in the chemotherapy of various tumors. Mitotic poisons are able to interfere with polymerization (stabilization) or depolymerization of tubulin, which in turn leads to the arrest of cells in the M-phase (named as a mitotic catastrophe) and their subsequent death via activation of apoptotic mechanisms. However, the effectiveness of MP-based therapies is gradually decreasing over the time due to development of multiple drug resistance mechanisms in cancer cells. Thus, development of novel compounds selectively targeting tubulin and effectively overcoming multiple drugresistance phenotype in cancer is an urgent need in current oncology. Aim. To examine the cytotoxic and antitumor activities of several pyrrole-containing heterocyclic compounds (EPC-91, EPC-92 and PCA-93) against cancer cell lines with epithelial and mesenchymal origin, including those with multiple drug resistance phenotype. Materials and methods. Studies were performed on parental human cancer cell lines – triple-negative breast cancer HCC1806, gastrointestinal stromal tumor GIST T-1, osteosarcoma SaOS-2, – sensitive to chemotherapy (paclitaxel, doxorubicin) and their resistant sublines (HCC1806 Tx-R, GIST T-1 Tx-R, SaOS-2 Dox-R), as well as on murine colorectal adenocarcinoma cell line Colon-26, exhibiting primary resistance to the aforementioned chemotherapeutic agents. Results. The cytotoxic activities of EPC-91 and PCA-93 were due to their abilities to depolymerize tubulin. The results of immunofluorescence microscopy and Western blotting indicated that the compounds disrupt assembly of tubulin microtubules and prevent polymerization of α-tubulin in cancer cells. Inhibition of tubulin polymerizations led to significant increasein number of round-shaped and phospho-histone 3 (e. g. mitotic) cells, followed by their death through apoptosis. PCA-93 also exhibited potent anti-tumor effect against Colon-26 cells due to its anti-proliferative and proapoptotic activities. Conclusion. The data shown here illustrates potent cytotoxic activities of EPC-91 and PCA-93 against multiple cancer cell lines in vitro including those with multiple drug resistance phenotype. Similarly, PCA-93 was found to be highly effective against Colon-26 cell in vivo, thereby illustrating the attractive platform for the development of novel pyrrole-based agents exhibiting potent anti-tumor activities.

5 June 2026 in Koloproktologia
Verified
Journal Article
Open access
PDF file
VEVasiliy Egorov
Vasiliy Egorov
FAFoat Sh. Akhmetzyanov
Foat Sh. Akhmetzyanov
DRDavid M. Ruvinsky
David M. Ruvinsky
AGAlina I. Gilyazova
Alina I. Gilyazova
DDDarya V. Dimitrieva
Darya V. Dimitrieva
VSVitaliy V. Strunkin
Vitaliy V. Strunkin
AIM: to assess early and long-term outcomes of interspincteric (ISR) and ultralow anterior resection (ULAR) for low rectal cancer, with a special focus on risk factors for a permanent stoma. PATIENTS AND METHODS: seventy patients who underwent ISR/ULAR for rectal cancer from January 2019 to December 2023 were included in retrospective study. Patients who underwent ULAR during the same time period was selected after matching by the following parameters: gender, age, body mass index, comorbidities, type of surgical approach, pTNM, tumor stage, degree of differentiation, distance of the tumor from the anus, type of neoadjuvant radiation therapy (n = 58). The overall median follow-up of patients in both groups was 38 (95% CI: 31–41) months. Surgical complications, stoma formation rate, three-year overall (OS) and three-year recurrence-free survival (RFS) were assessed. Multivariate logistic regression analysis was used to identify predictors of permanent stoma. RESULTS: anastomotic leakage was higher after ULAR: 17/58 (29.3%) vs. 10/70 (14.3%) (p = 0.038). Late complications, predominantly functional disorders, occurred more often after AAR: 35/67 (52.2%) vs. 14/55 (25.5%) (p = 0.003). Despite higher odds of stoma reversal after ULAR (odds ratio (OR) 6.5; 95% confidence interval (CI) 1.7–23.9), by the end of follow-up, a greater proportion of patients in this group were living with a permanent stoma: 27/56 (48.2%) vs. 15/67 (22.4%) (p = 0.003). Independent predictors of a permanent stoma were the performance of ULAR (adjusted odds ratio (AOR) 3.54; 95 CI: 1.373–9.13), anastomotic leakage (AOR 11.76; 95 CI: 3.46–40), pN + stage (AOR 1.73; 95 CI: 1.06–2.82) and radiotherapy (AOR 3.92; 95 CI: 1.17–13.09). The prognostic model showed high discriminative ability (Area Under the Curve (AUC) = 0.851; 95% CI: 0.772–0.929). Three-year OS (63.9% (95% CI: 49.9–74.9) vs. 75.0%, (95% CI: 59.7–85.2), p = 0.503) and RFS (48.2% (95% CI: 33.9–61.2) vs. 50.3% (95% CI: 31.2–66.7), p = 0.646) after AAR and ULAR, respectively, were statistically comparable. CONCLUSION : despite comparable oncological efficacy, ULAR is associated with a higher risk of anastomotic leakage, which is a key factor leading to a permanent stoma. AAR is associated with a higher rate of functional disorders. The choice of surgical technique should be based on an individual assessment of the risk of anastomotic leakage.